News

MyChesCo on MSN3mon
Palvella Therapeutics Reports Promising Results for QTORIN Rapamycin in Treating Rare Genetic Disease
has the potential to become the first approved therapy for this rare and debilitating disease in the United States.
Yahoo Finance5d
Palvella Therapeutics Granted Additional U.S. Patent for QTORIN™ Rapamycin for the Treatment of Microcystic Lymphatic Malformations
Microcystic LMs are a rare, chronically debilitating genetic disease caused by dysregulation of the phosphatidylinositol 3-kinase (PI3K)/mammalian target of rapamycin (mTOR) pathway. The disease ...
News-Medical.Net on MSN4d
New $15 million study aims to understand cardiovascular and kidney disease risk factors in women
Research teams from Augusta University, Massachusetts General Hospital and The Ohio State University will lead a $15 million project dedicated to studying the various ways that risk factors for ...
Nasdaq5d
Palvella Therapeutics Secures Fifth U.S. Patent for QTORIN™ Rapamycin, Advancing Treatment for Microcystic Lymphatic Malformations
About Microcystic Lymphatic Malformations Microcystic LMs are a rare, chronically debilitating genetic disease caused by dysregulation of the phosphatidylinositol 3-kinase (PI3K)/mammalian target ...
Nasdaq5d
Palvella Secures Fifth U.S. Patent For QTORIN Rapamycin In Microcystic Lymphatic Malformations
Palvella noted that QTORIN rapamycin may become the first FDA-approved treatment and standard of care for microcystic LMs ... therapy for this debilitating disease." QTORIN rapamycin has received ...